Get the Stockscreener App
233.23
3.58%
8.06
After Hours:
233.35
0.12
+0.05%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $233.23, with a volume of 8.34M.
It is up +3.58% in the last 24 hours and up +1.18% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$225.17
Open:
$225.4
24h Volume:
8.34M
Relative Volume:
1.53
Market Cap:
$412.01B
Revenue:
$59.64B
Net Income/Loss:
$2.36B
P/E Ratio:
175.98
EPS:
1.3253
Net Cash Flow:
$19.68B
1W Performance:
+7.59%
1M Performance:
+1.18%
6M Performance:
+22.71%
1Y Performance:
+36.32%
1-Day Range:
$225.29
$234.00
1-Week Range:
$215.65
$234.00
52-Week Range:
$163.81
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
233.23 | 386.54B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,017.78 | 865.16B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
194.39 | 453.94B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
132.29 | 244.07B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
91.45 | 215.32B | 63.90B | 19.05B | 13.05B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie and Calico end groundbreaking partnership after 11 years without an approved drug - The Business Journals
Will AbbVie Inc. stock announce special dividendStop Loss & High Conviction Investment Ideas - newser.com
Why AbbVie Inc. stock appears on watchlists2025 Price Action Summary & Verified Technical Signals - newser.com
AbbVie Shares Rise To Intraday High After Key Trading Signal - Benzinga
AbbVie Reportedly Ends Partnership With Alphabet-Backed Calico Life Sciences - Stocktwits
AbbVie (ABBV) Ends R&D Partnership with Calico Life Sciences - GuruFocus
How Much Did Skyrizi and Rinvoq Drive AbbVie's Q3 Performance? - Yahoo Finance
AbbVie reportedly ending R&D deal with Alphabet-backed antiaging firm Calico - Seeking Alpha
AbbVie Severs Ties With Google-Backed Aging Research Biotech - MarketScreener
AbbVie cuts ties with Google-backed longevity company, lays off scientists - statnews.com
AbbVie (ABBV) Surged Following Strong Results and Increased Guidance - Insider Monkey
How AbbVie Inc. (4AB) stock benefits from digital adoptionShort Setup & Daily Technical Forecast Reports - newser.com
Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders - The Manila Times
Daiwa Securities Adjusts Price Target on AbbVie to $226 From $214, Maintains Outperform Rating - MarketScreener
Fund Update: 81,625 ABBVIE (ABBV) shares added to THORNBURG INVESTMENT MANAGEMENT INC portfolio - Quiver Quantitative
AbbVie Has Many Bullish Attributes (Technical Analysis) - Seeking Alpha
NEXGEL (NXGL) Q3 2025 Earnings Call Transcript - The Motley Fool
Is AbbVie Inc. (4AB) stock undervalued after correctionSell Signal & Safe Entry Trade Reports - newser.com
Is AbbVie Inc. stock undervalued at current price2025 Price Action Summary & Community Driven Trade Alerts - newser.com
How reliable is AbbVie Inc. (4AB) stock dividend growthEarnings Risk Summary & Real-Time Volume Spike Alerts - newser.com
Ironwood surges after Q3 beat; raised outlook for AbbVie-partnered Linzess - MSN
How Analyst Views Are Shaping the Evolving Story for AbbVie - Yahoo Finance
Is AbbVie's (ABBV) Dividend Hike Amid Margin Pressures Shaping Its Investment Appeal? - Yahoo Finance
Can AbbVie Inc. stock retain market dominanceBear Alert & Fast Gain Swing Alerts - newser.com
Is AbbVie Inc. reversing from oversold territoryJuly 2025 Review & Technical Pattern Recognition Alerts - newser.com
Is AbbVie Inc. stock undervalued vs historical averagesWeekly Profit Recap & Capital Efficiency Focused Ideas - newser.com
Can momentum traders help lift AbbVie Inc.Quarterly Profit Review & Reliable Breakout Forecasts - newser.com
Is AbbVie Inc. stock resilient to inflationWeekly Trading Summary & Risk Managed Investment Strategies - newser.com
What Wall Street predicts for AbbVie Inc. stock priceWeekly Stock Report & Risk Controlled Swing Alerts - newser.com
Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer - Seeking Alpha
Piper Sandler Raises AbbVie (ABBV) Price Target to $289, Maintains Overweight Rating - Insider Monkey
Reversal indicators forming on AbbVie Inc. stockJuly 2025 Price Swings & Verified Momentum Stock Alerts - newser.com
Should AbbVie's (ABBV) Dividend Hike and Lower Guidance Prompt a Closer Look at Earnings Stability? - simplywall.st
UBS Adjusts Price Target on AbbVie to $220 From $195, Maintains Neutral Rating - MarketScreener
Harvest Portfolios Group Inc. Has $55.10 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Shaping the future of science, together - AbbVie
The Top 5 Analyst Questions From AbbVie’s Q3 Earnings Call - The Globe and Mail
Will AbbVie Inc. stock attract more institutional investorsWeekly Earnings Recap & Risk Adjusted Buy/Sell Alerts - newser.com
Why AbbVie Inc. stock is trending among retail traders2025 Support & Resistance & Long Hold Capital Preservation Tips - Fundação Cultural do Pará
Can AbbVie Inc. stock attract analyst upgradesWall Street Watch & Capital Efficient Trade Techniques - newser.com
Analyzing AbbVie Inc. with risk reward ratio chartsEarnings Overview Summary & Short-Term Swing Trade Alerts - newser.com
How AbbVie Inc. (4AB) stock performs in volatility spikes2025 Big Picture & Short-Term High Return Strategies - newser.com
How AbbVie Inc. stock performs in rising dollar environmentQuarterly Earnings Summary & High Yield Equity Trading Tips - newser.com
Market Rankings: Can AbbVie Inc. stock retain market dominanceGold Moves & Fast Moving Trade Plans - fcp.pa.gov.br
Jim Cramer Says “I Found the AbbVie Call Particularly Jarring” - MSN
Will AbbVie Inc. stock reach all time highs in 2025July 2025 Chart Watch & High Conviction Buy Zone Picks - fcp.pa.gov.br
AbbVie Just Raised Its Dividend by 5.5%. Should You Buy ABBV Stock Here? - Barchart.com
Ironwood wins FDA label expansion for bowel disease drug developed with AbbVie - Seeking Alpha
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):